IPO Trending
MANKINDEQ / NSE, BSEListed

Mankind Pharma Limited

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across a wide range of acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands such as Manforce, Moxikind-CV, Amlokind-AT, Prega News, and Gudcef, supported by one of the largest distribution networks of medical representatives in India, with over 80% of doctors prescribing its formulations. Ranked 4th in domestic sales in FY2022, Mankind Pharma has received numerous awards, including The Best of Bharat Awards 2022, National Awards for Manufacturing Competitiveness Silver Medal 2021, and recognition for Best Design in Healthcare and performance management excellence.

₹1,026 - ₹1,08015.32x sub
Listed Price1300.00
Listing Gain+20.37%
Peer Comparison-Financial performance and valuation from the IPO detail feed
Peer comparison data is not available for this IPO yet.